Press Release
« Back
TG Therapeutics, Inc. Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014
Apr 07, 2014
The schedule for the Company's poster presentations is as follows:
-- Title: The PI3K-δ inhibitor TGR-1202 in combination with Brentuximab Vedotin (SGN-35) synergistically induces G2/M phase arrest and cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell lines
- Abstract Number: 4711
-
Presentation Date & Time: Tuesday, April 08, 2014,
1:00 PM - 5:00 PM PT - Location: Hall A-E, Poster Section 37
- Poster Board Number: 27
- Presenter: Silvia L. Locatelli, PhD
-- Title: The PI3K-δ inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro
- Abstract Number: 4518
-
Presentation Date & Time: Tuesday, April 08, 2014,
1:00 PM - 5:00 PM PT - Location: Hall A-E, Poster Section 30
- Poster Board Number: 4
- Presenter: Daphne R. Friedman, MD
A copy of the above referenced abstracts can be viewed online through the AACR meeting website at www.aacr.org. Following the presentations the posters will be available on the Company's website, www.tgtherapeutics.com, in the Publications section found under the Pipeline tab.
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not
produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4484 Email: ir@tgtxinc.com
News Provided by Acquire Media